Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.
Cruijsen M, Hobo W, van der Velden WJFM, Bremmers MEJ, Woestenenk R, Bär B, Falkenburg JHF, Kester M, Schaap NPM, Jansen J, Blijlevens NNM, Dolstra H, Huls G. Cruijsen M, et al. Among authors: bar b. Biol Blood Marrow Transplant. 2016 Jun;22(6):1000-1008. doi: 10.1016/j.bbmt.2016.02.003. Epub 2016 Feb 6. Biol Blood Marrow Transplant. 2016. PMID: 26860635 Free article.
Low relapse risk in poor risk AML after conditioning with 10-day decitabine, fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation.
Cruijsen M, Hilberink JR, van der Velden WJFM, Jansen JH, Bär B, Schaap NPM, de Haan A, Mulder AB, de Groot MR, Baron F, Vellenga E, Blijlevens NNM, Huls G. Cruijsen M, et al. Among authors: bar b. Bone Marrow Transplant. 2021 Aug;56(8):1964-1970. doi: 10.1038/s41409-021-01272-3. Epub 2021 Apr 6. Bone Marrow Transplant. 2021. PMID: 33824442 Free article. Clinical Trial.
In relapsed patients after lymphocyte depleted bone marrow transplantation the percentage of donor T lymphocytes correlates well with the outcome of donor leukocyte infusion.
Schattenberg A, Schaap N, Van De Wiel-Van Kemenade E, Bär B, Preijers F, Van Der Maazen R, Roovers E, De Witte T. Schattenberg A, et al. Among authors: bar b. Leuk Lymphoma. 1999 Jan;32(3-4):317-25. doi: 10.3109/10428199909167392. Leuk Lymphoma. 1999. PMID: 10037029 Clinical Trial.
Prospective evaluation of sequential treatment of sclerotic chronic graft versus host disease with rituximab and nilotinib.
van der Wagen L, Te Boome L, Schiffler M, Nijhof I, Schoordijk M, van Dorp S, van Dijk M, Raymakers R, Petersen E, de Witte M, de Jong N, Bellido M, Bär B, Meijer E, Kuball J. van der Wagen L, et al. Among authors: bar b. Bone Marrow Transplant. 2018 Oct;53(10):1255-1262. doi: 10.1038/s41409-018-0158-9. Epub 2018 Mar 16. Bone Marrow Transplant. 2018. PMID: 29549292 Clinical Trial.
Tyrosine kinase inhibitor levels matter in treating chronic GVHD.
van der Wagen L, Janssen J, Raijmakers R, Petersen E, de Witte M, de Jong N, Bellido M, Meijer E, Bär B, Jan Boelens J, Huitema A, Kuball J. van der Wagen L, et al. Among authors: bar b. Bone Marrow Transplant. 2019 Jul;54(7):1141-1144. doi: 10.1038/s41409-018-0429-5. Epub 2019 Jan 16. Bone Marrow Transplant. 2019. PMID: 30651587 Clinical Trial. No abstract available.
65 results